Equities analysts expect Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) to report sales of $2.17 billion for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Valeant Pharmaceuticals Intl’s earnings, with the highest sales estimate coming in at $2.24 billion and the lowest estimate coming in at $2.09 billion. Valeant Pharmaceuticals Intl reported sales of $2.40 billion in the same quarter last year, which would indicate a negative year over year growth rate of 9.6%. The company is expected to report its next earnings results before the market opens on Wednesday, February 28th.
On average, analysts expect that Valeant Pharmaceuticals Intl will report full year sales of $2.17 billion for the current fiscal year, with estimates ranging from $8.65 billion to $8.80 billion. For the next fiscal year, analysts forecast that the company will post sales of $8.46 billion per share, with estimates ranging from $7.96 billion to $9.16 billion. Zacks’ sales averages are a mean average based on a survey of research analysts that cover Valeant Pharmaceuticals Intl.
A number of research firms have recently weighed in on VRX. Goldman Sachs Group began coverage on shares of Valeant Pharmaceuticals Intl in a research note on Wednesday, January 24th. They issued a “sell” rating and a $18.00 price target on the stock. Cantor Fitzgerald set a $25.00 price target on shares of Valeant Pharmaceuticals Intl and gave the company a “buy” rating in a research note on Friday, January 19th. Wells Fargo & Co restated a “sell” rating and issued a $9.00 price target on shares of Valeant Pharmaceuticals Intl in a research note on Tuesday, January 16th. HC Wainwright raised their price target on shares of Valeant Pharmaceuticals Intl from $17.00 to $24.00 and gave the company a “buy” rating in a research note on Tuesday, January 16th. Finally, Zacks Investment Research downgraded shares of Valeant Pharmaceuticals Intl from a “hold” rating to a “strong sell” rating in a research note on Saturday, January 13th. Seven investment analysts have rated the stock with a sell rating, nine have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $18.59.
Shares of Valeant Pharmaceuticals Intl (NYSE:VRX) opened at $18.88 on Friday. Valeant Pharmaceuticals Intl has a one year low of $8.31 and a one year high of $24.43. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 4.84. The firm has a market cap of $6,570.00, a P/E ratio of 4.84, a PEG ratio of 0.58 and a beta of -0.42.
ILLEGAL ACTIVITY WARNING: “Zacks: Brokerages Anticipate Valeant Pharmaceuticals Intl Inc (VRX) Will Post Quarterly Sales of $2.17 Billion” was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.chaffeybreeze.com/2018/02/18/zacks-brokerages-anticipate-valeant-pharmaceuticals-intl-inc-vrx-will-post-quarterly-sales-of-2-17-billion.html.
About Valeant Pharmaceuticals Intl
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.